Johnson & Johnson
Johnson & Johnson
JNJ · NYSE
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $94.2B
- Assets
- $199.2B
- SEC filing
- DEF 14A
- Filed
- March 11, 2026
Executive Compensation
Compensation reported for Johnson & Johnson’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
Joaquin Duato
Chairman/CEO
$32.8M
Reported total
- Salary
- $1,600,000
- Stock awards
- $15,028,948
- Incentives
- $4,298,700
- Option awards
- $5,927,995
- Other
- $5,902,468
Joseph Wolk
EVP, CFO
$14.4M
Reported total
- Salary
- $1,240,646
- Stock awards
- $6,263,486
- Incentives
- $1,860,560
- Option awards
- $2,470,503
- Other
- $2,570,247
J. Taubert
EVP, WWC Innovative Medicine
$14M
Reported total
- Salary
- $1,220,308
- Stock awards
- $6,160,665
- Incentives
- $2,002,750
- Option awards
- $2,430,013
- Other
- $2,216,327
J. Reed
EVP, Innovative Medicine, R&D
$12.2M
Reported total
- Salary
- $1,220,308
- Stock awards
- $6,160,665
- Incentives
- $1,810,000
- Option awards
- $2,430,013
- Other
- $593,076
T. Schmid
EVP, WWC, Med Tech
$9.3M
Reported total
- Salary
- $942,308
- Stock awards
- $3,422,473
- Incentives
- $1,507,800
- Option awards
- $1,349,998
- Other
- $2,114,186
Joaquin Duato
Chairman/CEO
$32.8M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed March 11, 2026.
- Salary
- $1.6M
- Stock Awards
- $15M
- Option Awards
- $5.9M
- Incentives
- $4.3M
- Other
- $5.9M
Historical Compensation
Joaquin Duato total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,600,000 | $15,028,948 | $32,758,111 |
| 2024 | $1,600,000 | $10,787,159 | $24,302,360 |
| 2023 | $1,584,615 | $11,182,143 | $28,397,240 |
Named Executive Officers
Joaquin Duato
Chairman/CEO
Johnson & Johnson · JNJ
$32.8M
FY 2025 · DEF 14A
Joseph Wolk
EVP, CFO
Johnson & Johnson · JNJ
$14.4M
FY 2025 · DEF 14A
J. Taubert
EVP, WWC Innovative Medicine
Johnson & Johnson · JNJ
$14M
FY 2025 · DEF 14A
J. Reed
EVP, Innovative Medicine, R&D
Johnson & Johnson · JNJ
$12.2M
FY 2025 · DEF 14A
T. Schmid
EVP, WWC, Med Tech
Johnson & Johnson · JNJ
$9.3M
FY 2025 · DEF 14A
Source information
- Company
- Johnson & Johnson
- Ticker
- JNJ · NYSE
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- March 11, 2026
- SEC accession number
- 0000200406-26-000063
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company →
Pfizer
Pfizer Inc.
PFE · NYSE
A. Bourla
Chairman And Chief Executive Officer
$27.6M
FY 2025 reported total
View company →
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company →
Merck
Merck & Co., Inc.
MRK · NYSE
Robert M. Davis
Chairman, Chief Executive Officer And President
$20.8M
FY 2025 reported total
View company →